drug
ENHERTU
updated 3mo agoby Daiichi Sankyo Co Ltd
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying ENHERTU
- phase2A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
- phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- phase2Castrate Resistant Prostate Cancer Enhertu Therapy
- phase1Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
- phase1ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- phase2StrataPATH™ (Precision Indications for Approved Therapies)
News(10)
- AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, EnhertuAstraZeneca on Monday reported successes in two late-stage trials in different forms of lung cancer — one with a two-drug combination of Tagrisso and Orpathys and another with its blockbuster antib…endpoints · 3d ago
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 18d ago
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.biospace · 22d ago
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.fiercebiotech · 25d ago
- ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFor years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…fiercebiotech · 1mo ago
- Merck ADC, in China study, shows potential to replace chemo in lung cancerThe results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.biopharma_dive · 1mo ago
- STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and moreA U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching an agreement allowing Teva to market a generic version of Forteostat · 1mo ago
- STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patentsA group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.stat · 1mo ago
- STAT+: Pharmalittle: We’re reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and moreU.S. health secretary Robert F. Kennedy Jr. is pressing forward with his effort to help Americans stop taking SSRI antidepressantsstat · 1mo ago
- STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and moreGerman lawmakers passed a bill that would more than double the discount on branded medicines drugmakers must provide the governmentstat · 1mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that